Status:
UNKNOWN
Relationship Between Topiramate Use and Ocular Angle Status
Lead Sponsor:
Chinese University of Hong Kong
Collaborating Sponsors:
Hong Kong Eye Hospital
Conditions:
Glaucoma, Angle-Closure
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
We test the hypothesis whether topiramate narrows the angles which may render Asians more likely to suffer from acute angle closure glaucoma.
Detailed Description
Topiramate is approved for the treatment of epilepsy and prophylaxis of migraine attacks. There were case reports of acute angle closure glaucoma (AACG) associated with its use. AACG is particularly c...
Eligibility Criteria
Inclusion
- Participants aged 18-75 with an indication for starting topiramate.
Exclusion
- Patients with known allergy or intolerance to topiramate.
- Recent exposure to topiramate (\<3 months).
- Moderate to severe renal failure.
- Known history of renal calculi or hepatic failure
- Inability to give informed consent.
- Pregnant women or women of child-bearing age who do not practise an acceptable means of contraception.
- Patients known to have angle-closure glaucoma.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00153699
Start Date
September 1 2004
End Date
July 1 2007
Last Update
October 31 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hong Kong Eye Hospital
Kowloon, Hong Kong
2
Prince of Wales Hospital
Shatin, Hong Kong